LLY
Eli Lilly and Company NYSE$963.33
Mkt Cap $865.1B
52w Low $623.78
66.6% of range
52w High $1133.95
50d MA $950.57
200d MA $909.66
P/E (TTM)
41.9x
EV/EBITDA
35.8x
P/B
32.6x
Debt/Equity
1.6x
ROE
77.8%
P/FCF
107.6x
RSI (14)
—
ATR (14)
—
Beta
0.50
50d MA
$950.57
200d MA
$909.66
Avg Volume
3.3M
About
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The compa…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | TNS | 6.97 | 8.55 | +22.7% | 934.60 | +1.5% | +3.1% | — | — | — | — | — | — |
| Feb 4, 2026 | TNS | 6.91 | 7.54 | +9.1% | 1107.12 | -3.8% | -7.8% | -4.4% | -5.6% | -7.5% | -8.3% | -10.5% | — |
| Oct 30, 2025 | TNS | 5.69 | 7.02 | +23.4% | 844.50 | -0.6% | +2.2% | +6.2% | +7.4% | +9.6% | +11.0% | +25.3% | — |
| Aug 7, 2025 | TNS | 5.60 | 6.31 | +12.7% | 640.86 | +2.2% | -2.4% | -0.9% | -0.2% | +3.1% | +6.8% | +15.3% | — |
| May 1, 2025 | TNS | 3.26 | 3.34 | +2.5% | 794.10 | +3.9% | +3.7% | +3.4% | -2.4% | -2.2% | -5.4% | -5.9% | — |
| Feb 6, 2025 | TNS | 5.03 | 5.32 | +5.8% | 870.37 | +0.7% | +0.9% | -0.2% | -0.6% | +0.3% | +0.2% | -4.7% | — |
| Oct 30, 2024 | TNS | 1.47 | 1.18 | -19.7% | 846.83 | -1.2% | -2.0% | -3.3% | -4.8% | -4.8% | -8.3% | -6.1% | — |
| Aug 8, 2024 | TNS | 2.60 | 3.92 | +50.8% | 845.31 | +1.7% | +5.5% | +4.6% | +7.4% | +10.2% | +10.2% | +7.4% | — |
| Apr 30, 2024 | TNS | 2.46 | 2.58 | +4.9% | 781.10 | -0.8% | -0.6% | -3.2% | -5.9% | -1.8% | -0.4% | +4.3% | — |
| Feb 6, 2024 | TNS | 2.22 | 2.49 | +12.2% | 705.03 | +0.8% | +2.9% | +4.3% | +5.0% | +4.6% | +5.4% | +10.7% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $934.60 | $948.95 | +1.5% | +3.1% | — | — | — | — |
| Apr 22 | Guggenheim | Maintains | Buy → Buy | — | $903.02 | $906.40 | +0.4% | +2.0% | +1.6% | -2.1% | -3.8% | -3.2% |
| Apr 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $955.19 | $963.69 | +0.9% | -1.6% | -2.7% | -3.4% | -5.3% | -5.4% |
| Apr 2 | BofA Securities | Maintains | Buy → Buy | — | $954.52 | $945.00 | -1.0% | -2.0% | -2.9% | -2.5% | -0.1% | +0.1% |
| Mar 30 | Guggenheim | Maintains | Buy → Buy | — | $878.24 | $888.48 | +1.2% | +1.0% | +4.7% | +8.7% | +6.5% | +5.6% |
| Mar 17 | HSBC | Downgrade | Hold → Reduce | — | $989.12 | $978.92 | -1.0% | -5.9% | -7.2% | -7.2% | -8.3% | -7.9% |
| Feb 10 | Freedom Broker | Upgrade | Hold → Buy | — | $1044.67 | $1050.66 | +0.6% | -1.9% | -2.8% | -0.6% | -0.4% | -0.8% |
| Feb 9 | Deutsche Bank | Maintains | Buy → Buy | — | $1058.18 | $1077.09 | +1.8% | -1.3% | -3.2% | -4.1% | -1.9% | -1.7% |
| Feb 5 | Morgan Stanley | Maintains | Overweight → Overweight | — | $1107.12 | $1065.50 | -3.8% | -7.8% | -4.4% | -5.6% | -7.5% | -8.3% |
| Feb 5 | JP Morgan | Maintains | Overweight → Overweight | — | $1107.12 | $1065.50 | -3.8% | -7.8% | -4.4% | -5.6% | -7.5% | -8.3% |
Recent Filings
8-K · 8.01
!! High
Kyverna Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Kyverna Therapeutics announced a material event; details are available in the attached press release filed as Exhibit 99.1, likely involving its pipeline or strategic partnerships.
May 4
8-K
Eli Lilly and Company -- 8-K Filing
Eli Lilly's strong Q1 2026 results—revenue up 56% to $19.8B and EPS up 170% to $8.26—combined with raised full-year guidance demonstrate robust momentum despite Mounjaro/Zepbound price pressure, signaling sustained growth.
Apr 30
8-K · 5.02
!!! Very High
Vaxart, Inc. -- 8-K 5.02: Executive Change
Vaxart appoints James B. Breitmeyer as Chief Executive Officer, signaling leadership transition that investors should monitor for strategic direction and operational changes.
Apr 23
8-K · 1.02
!! High
Rigel Pharmaceuticals Inc. (New) -- 8-K 1.02: Material Agreement Terminated
Rigel Pharmaceuticals terminated its CNS disease program effective June 15, 2026, eliminating a potential revenue stream and narrowing its pipeline focus to other therapeutic areas.
Apr 21
8-K · 7.01
! Medium
Neurogene, Inc. -- 8-K 7.01: Regulation FD Disclosure
Neurogene disclosed material information via press release but the 8-K summary doesn't specify the content, so investors should review Exhibit 99.1 directly to assess relevance to NGNE stock.
Apr 20
8-K
Unknown — 8-K Filing
LLY's acquisition of a target company includes contingent value rights tied to future milestones, meaning shareholders benefit only if specific operational or financial goals are met, adding execution risk to the deal.
Mar 31
8-K
Unknown — 8-K Filing
Directors gain broad indemnification coverage for legal expenses and settlements, which may reduce accountability for questionable decisions and increase shareholder litigation risk and governance concerns.
Mar 26
8-K · 7.01
! Medium
Zura Bio Limited Class A -- 8-K 7.01: Regulation FD Disclosure
Zura Bio disclosed material information via press release on February 23, 2026, subject to Regulation FD requirements without admitting materiality determinations for investor consideration.
Feb 23
8-K
Eli Lilly & Co. -- 8-K Filing
Eli Lilly exceeded expectations with Q4 2025 revenue surging 43% to $19.3 billion, driven by blockbuster diabetes drugs Mounjaro and Zepbound, while EPS jumped 51% to $7.39 reported.
Feb 4
Data updated apr 25, 2026 7:22pm
· Source: massive.com